(GETI-B) Getinge ser. - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000202624

Medical Equipment, Surgical Tools, Ventilation Systems, Monitoring Devices, Sterilization

GETI-B EPS (Earnings per Share)

EPS (Earnings per Share) of GETI-B over the last years for every Quarter: "2020-03": 0.99, "2020-06": 1.81, "2020-09": 5.07, "2020-12": 4.02, "2021-03": 2.36, "2021-06": 2.93, "2021-09": 2.78, "2021-12": 2.83, "2022-03": 1.96, "2022-06": 2.21, "2022-09": 2.93, "2022-12": 2.04, "2023-03": 2.15, "2023-06": 0.79, "2023-09": 3.28, "2023-12": 2.63, "2024-03": 1.69, "2024-06": 1.88, "2024-09": 0.01, "2024-12": 2.44, "2025-03": 1.1,

GETI-B Revenue

Revenue of GETI-B over the last years for every Quarter: 2020-03: 6033, 2020-06: 6971, 2020-09: 7976, 2020-12: 8839, 2021-03: 6169, 2021-06: 6587, 2021-09: 6306, 2021-12: 7988, 2022-03: 6182, 2022-06: 6670, 2022-09: 6941, 2022-12: 8498, 2023-03: 7141, 2023-06: 7176, 2023-09: 7607, 2023-12: 9903, 2024-03: 7513, 2024-06: 8305, 2024-09: 7870, 2024-12: 11071, 2025-03: 8320,

Description: GETI-B Getinge ser.

Getinge AB ser. B is a Swedish healthcare company that provides a wide range of medical equipment and solutions for hospitals and healthcare facilities worldwide. The companys product portfolio includes equipment for operating rooms, intensive care units, and sterilization departments, such as extracorporeal membrane oxygenation, mechanical ventilation, and advanced patient monitoring.

The companys business is divided into three main segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge AB has a strong presence in the global healthcare market, with a network of sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region.

From a financial perspective, Getinge AB has a market capitalization of approximately 52.3 billion SEK, with a price-to-earnings ratio of 35.46 and a forward P/E of 17.21. The companys return on equity is 4.72%, indicating a relatively modest level of profitability. To further analyze the companys financial health, we can examine additional KPIs such as debt-to-equity ratio, interest coverage ratio, and operating margin.

Some key performance indicators (KPIs) to monitor for Getinge AB include revenue growth, gross margin, and research and development (R&D) expenses as a percentage of sales. The companys ability to innovate and bring new products to market is crucial in the highly competitive healthcare equipment industry. Additionally, metrics such as customer satisfaction, product reliability, and after-sales support are essential in driving customer loyalty and retention.

To evaluate the investment potential of Getinge AB, we can analyze the companys competitive position, market trends, and growth prospects. The global healthcare equipment market is driven by factors such as aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Getinge ABs diversified product portfolio and strong global presence position the company for potential long-term growth.

Additional Sources for GETI-B Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

GETI-B Stock Overview

Market Cap in USD 5,367m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception

GETI-B Stock Ratings

Growth Rating -12.5
Fundamental 39.4
Dividend Rating 60.6
Rel. Strength 15.7
Analysts -
Fair Price Momentum 174.87 SEK
Fair Price DCF 199.10 SEK

GETI-B Dividends

Dividend Yield 12m 2.40%
Yield on Cost 5y 2.41%
Annual Growth 5y 7.96%
Payout Consistency 94.3%
Payout Ratio 50.3%

GETI-B Growth Ratios

Growth Correlation 3m 18%
Growth Correlation 12m -21%
Growth Correlation 5y -25.8%
CAGR 5y -0.19%
CAGR/Max DD 5y 0.00
Sharpe Ratio 12m 0.06
Alpha -3.33
Beta 0.395
Volatility 31.76%
Current Volume 455.1k
Average Volume 20d 474.3k
Stop Loss 183.7 (-3%)
What is the price of GETI-B shares?
As of July 18, 2025, the stock is trading at SEK 189.40 with a total of 455,113 shares traded.
Over the past week, the price has changed by -1.87%, over one month by +2.99%, over three months by +0.06% and over the past year by +3.72%.
Is Getinge ser. a good stock to buy?
Partly, yes. Based on ValueRay´s Fundamental Analyses, Getinge ser. (ST:GETI-B) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 39.43 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GETI-B is around 174.87 SEK . This means that GETI-B is currently overvalued and has a potential downside of -7.67%.
Is GETI-B a buy, sell or hold?
Getinge ser. has no consensus analysts rating.
What are the forecasts for GETI-B share price target?
According to our own proprietary Forecast Model, GETI-B Getinge ser. will be worth about 194 in July 2026. The stock is currently trading at 189.40. This means that the stock has a potential upside of +2.43%.
Issuer Target Up/Down from current
Wallstreet Target Price 235.2 24.2%
Analysts Target Price - -
ValueRay Target Price 194 2.4%